- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.04. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in the company's rights issue | 1 | Cision News | ||
| 16.04. | DIAMYD MEDICAL AB: Diamyd Medical announces preliminary outcome in the company's rights issue | 1 | Cision News | ||
| 12.04. | Diamyd Medical AB: Recruitment milestone reached in Diamyd® Phase 3 trial | 265 | PR Newswire | STOCKHOLM, April 12, 2024 /PRNewswire/ -- Diamyd Medical's precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse events... ► Artikel lesen | |
| 11.04. | DIAMYD MEDICAL AB: Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes | 1 | Cision News | ||
| 05.04. | DIAMYD MEDICAL AB: Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue | 1 | Cision News | ||
| 28.03. | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Diamyd Medical AB | 173 | GlobeNewswire | With effect from April 02, 2024, the unit rights in Diamyd Medical AB will be
traded on First North Growth Market. Trading will continue up until and
including April 11, 2024.
Instrument: Unit... ► Artikel lesen | |
| 28.03. | DIAMYD MEDICAL AB: Diamyd Medical publishes prospectus with regards to the rights issue | 2 | Cision News | ||
| 25.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2024 | 135 | Xetra Newsboard | Das Instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY wird ex Kapitalmassnahme gehandelt am 25.03.2024 The instrument P0X FR001400N1P4 PHARNEXT EO -,10 EQUITY is traded ex capital adjustment on 25.03.2024Das... ► Artikel lesen | |
| 18.03. | DIAMYD MEDICAL AB: The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million | 1 | Cision News | ||
| 29.02. | DIAMYD MEDICAL AB: Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA | 2 | Cision News | ||
| 15.02. | Diamyd Medical AB: Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd® | 403 | PR Newswire | STOCKHOLM, Feb. 15, 2024 /PRNewswire/ -- Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum) that... ► Artikel lesen | |
| 14.02. | DIAMYD MEDICAL AB: Publication in Diabetologia highlights AI's potential for Type 1 Diabetes screening | 2 | Cision News | ||
| 24.01. | DIAMYD MEDICAL AB: In-depth analysis of Diamyd® Phase II trial further supports value of preserved insulin secretion | 1 | Cision News | ||
| 24.01. | Diamyd Medical AB (publ): Quarterly Report I 23/24 | 35 | GlobeNewswire (Europe) | September 2023 - November 2023, Diamyd Medical AB (publ), Fiscal year 2023/2024
Precision Medicine for Autoimmune Diabetes in Pivotal Phase 3
Diamyd Medical's B-share is traded on Nasdaq First North... ► Artikel lesen | |
| 08.01. | Diamyd Medical AB: Diamyd Medical gains market research findings to guide U.S. commercial strategy | 267 | PR Newswire | STOCKHOLM, Jan. 8, 2024 /PRNewswire/ -- Market research including initial interviews with US health care practitioners as well as US payers demonstrated a strong willingness to consider prescribing... ► Artikel lesen | |
| 04.01. | DIAMYD MEDICAL AB: Diamyd® precision medicine Phase 3 trial key interim analysis in July | 1 | Cision News | ||
| 06.12.23 | DIAMYD MEDICAL AB: Diamyd Medical's Precision Medicine patent for the prevention and treatment of autoimmune diabetes granted in South Korea | 1 | Cision News | ||
| 30.11.23 | Bulletin from Annual General Meeting of Diamyd Medical AB | 1 | Cision News | ||
| 29.11.23 | DIAMYD MEDICAL AB: Annual Report 2022/2023 | 1 | Cision News | ||
| 22.11.23 | Nasdaq Stockholm AB: New equity rights for trading, Diamyd Medical AB (596/23) | 363 | GlobeNewswire | At the request of Diamyd Medical AB, Diamyd Medical AB equity rights will be
traded on First North as from November 24, 2023.
Security name: Diamyd Medical AB TO 3 B
----------------------------------------
Short... ► Artikel lesen |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 156,78 | -0,04 % | AbbVie's Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritis | WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) Thursday announced positive results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination with a 26-week steroid taper regimen in... ► Artikel lesen | |
| ABBOTT LABORATORIES | 99,00 | -0,89 % | It's Draft Day: Damar Hamlin Helps Build the Abbott HeartMates Team | NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / AbbottEleven new HeartMates with 11 inspiring stories recognized at Abbott HeartMates Draft Day event in NYC.AbbottJust a week before the pro football... ► Artikel lesen | |
| BEVCANNA ENTERPRISES | 1,335 | +3,49 % | Bevcanna Enterprises Inc (3): Bevcanna to issue 169,816 shares for debt | ||
| ZOETIS | 140,78 | -0,16 % | Dividendenbekanntmachungen (18.04.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABSA GROUP LIMITED ADR US00400T1025 0,5706 USD 0,5347 EUR AKER ASA NO0010234552 15,5 NOK 1,3202 EUR ANORA GROUP OYJ FI4000292438 - 0... ► Artikel lesen | |
| BIONANO GENOMICS | 0,761 | 0,00 % | Bionano Genomics: Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing | SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping... ► Artikel lesen | |
| CASSAVA SCIENCES | 19,395 | +0,10 % | Cassava Sciences, Inc.: Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials | An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials... ► Artikel lesen | |
| WUXI BIOLOGICS | 1,551 | +0,52 % | Aktie von Wuxi Biologics Cayman: Kurs heute nahezu konstant (1,64 €) | CODE Die Aktie kostete zuletzt 1,64 Euro. Die Wertschätzung der Börsenteilnehmer für der Anteilsschein von Wuxi Biologics Cayman hat sich heute kaum verändert. Das Wertpapier liegt aktuell nur minimal... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 15,540 | +0,32 % | Aktien New York: Indizes bauen Gewinne aus - Inflationsdaten im Fokus | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben nach einem trägen Wochenstart am Dienstag zugelegt. Allerdings reagierten die Aktienkurse erst mit einiger Verzögerung positiv auf US-Inflationsdaten... ► Artikel lesen | |
| TRULIEVE CANNABIS | 10,220 | +1,09 % | Trulieve Cannabis Corp. - 8-K, Current Report | ||
| TG THERAPEUTICS | 12,828 | -1,93 % | TG Therapeutics, Inc.: TG Therapeutics Announces Additional Data Presentations for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting | NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy)... ► Artikel lesen | |
| DAIICHI SANKYO | 28,680 | +1,41 % | Daiichi Sankyo: ENHERTU Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors | Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca's ENHERTU that showed clinically meaningful responses across a broad range of tumors
ENHERTU now has five approved indications... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 13,855 | -1,98 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 | ||
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
| ERGOMED | 14,680 | 0,00 % | Ergomed plc: Ergomed strongly positioned for future growth in new partnership with Permira | PRESS RELEASE
Ergomed strongly positioned for future growth in new partnership with Permira
Permira completes acquisition of Ergomed for £703.1 millionThrough this partnership, Permira will... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 356,70 | -1,11 % | Dividendenbekanntmachungen (23.04.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,1 EUR AECOM US00766T1007 0,22 USD 0,2065 EUR ALLREAL HOLDING AG CH0008837566 3,5 CHF 3,6021... ► Artikel lesen |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,789 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
